Previous edition: SCWD 2025. Community figures from the conference and abstract submissions.
Participants
400+
Faculty members
100+
Abstracts submitted
220+
Countries
30+
Why attend in person
The 2026 programme is built for exchange: keynotes that bridge laboratory and clinic, discussion time after the talks, poster sessions and dedicated formats for early-career researchers.
Basic science and clinical practice share the stage.
The Opening Session pairs the “Prometheus” basic science keynote, Denis Guttridge (USA) on cachexia and the immune tumor macroenvironment, with the “Hippocrates” clinical keynote by Jeffrey Crawford (USA): cancer and cachexia, an oncologist’s perspective.
Thursday, December 10 · 13:00–14:00 · Hall A
Discussion is built into the programme.
Many sessions close with dedicated discussion time. Poster viewing and rapid-fire abstract sessions run on Thursday and Friday, with posters again on Saturday, and Thursday ends with a welcome reception and joint poster viewing.
Two halls run in parallel sessions, so you choose your own route through the three days.
Welcome reception · Thursday, December 10 · 18:45–19:45
A way in for early‑career researchers.
The Ken Fearon Career Café, Meet the Mentor, opens Friday morning, with attendance upon application and confirmation. Saturday starts with the Young Investigators Award Session. Doctors under 35, scientists, nurses and students register in their own fee category.
Career Café · Friday, December 11 · 07:00 (to be confirmed) Young Investigators Award Session · Saturday, December 12 · 08:00–09:00
Washington, DCThe United States Capitol at dawn. Photo: Architect of the Capitol, public domain.
The people moving the field forward
Researchers and clinicians announced on the 2026 programme, from fundamental discoveries to clinical evidence and emerging therapies.
Teresa Zimmers
USA
OHSU Knight Cancer Institute, Oregon Health & Science University
Thu, Dec 10 · 13:00Chair, Opening Session
Oregon Health & Science University
Kamyar Kalantar-Zadeh
UCLA David Geffen School of Medicine · Harbor-UCLA Medical Center
Fri, Dec 11 · 08:30Cachexia in CKD and AKI
Eric Roeland
USA
OHSU Knight Cancer Institute, Oregon Health & Science University
Fri, Dec 11 · 11:45GDF15 inhibition to reduce cachexia and promote anti-tumor therapy
Oregon Health & Science University
Marilia Seelaender
University of São Paulo · Faculty of Medicine
Thu, Dec 10 · 08:30Cachexia as multi-organ disease
Denis Guttridge
USA
Medical University of South Carolina · Hollings Cancer Center
Thu, Dec 10 · 13:00“Prometheus” keynote: cachexia and the immune tumor macroenvironment
Jeffrey Crawford
USA
Duke University School of Medicine · Duke Cancer Institute
Thu, Dec 10 · 13:00“Hippocrates” keynote: cancer and cachexia, an oncologist’s perspective
Stefan Anker
Germany
Charité – Universitätsmedizin Berlin
Fri, Dec 11 · 11:45Relevant endpoints for clinical trials in cancer cachexia
David Glass
USA
Regeneron Pharmaceuticals
Sat, Dec 12 · 10:00Myostatin/activin-pathway combination-therapy trial data
Dan Marks
USA
Kalohexis
Fri, Dec 11 · 11:45MC3/MC4R inhibition for cachexia
Katsu Funai
USA
University of Utah
Thu, Dec 10 · 14:15Sex-dependent decreases in organ weight with GLP-1RA
Faisal Beg
Canada
Simon Fraser University
Fri, Dec 11 · 18:00Automated CT/L3-based body composition pipelines and AI-based opportunistic screening
Gustavo Duque
Canada
McGill University
Fri, Dec 11 · 14:15Co-chair, Defining cachexia, sarcopenia, and frailty
Lynda Bonewald
USA
Indiana University School of Medicine
Sat, Dec 12 · 14:00General bone–muscle crosstalk: mechanisms and implications
Ed Reznik
USA
Memorial Sloan Kettering Cancer Center
Fri, Dec 11 · 18:00Defining cachexia staging and phenotypes using data from a large health system
Memorial Sloan Kettering Cancer Center
Andrew Coats
Australia
Heart Research Institute, Sydney
Fri, Dec 11 · 11:45s-pindolol
Stephan von Haehling
Germany
University Medical Center Göttingen
Fri, Dec 11 · 14:15Secondary sarcopenia in chronic disease: when muscle loss is not just ageing
Maurizio Muscaritoli
Italy
Sapienza University of Rome
Thu, Dec 10 · 14:15Can high protein diet prevent muscle wasting?
Ben Kirk
Australia
The University of Melbourne
Fri, Dec 11 · 14:15The conceptual and operational definition of sarcopenia
Speakers as announced on society-scwd.org. Programme subject to change. Logos identify each speaker’s institution and do not imply sponsorship.
Full programme
Bring your questions. Join the conversation.
Three days in Washington, DC. Connect the science with the people behind it.
Present, ask, discuss, meet. Beyond the scientific sessions, the three days include formats built for exchange.
Thu, Dec 10 · 13:00–14:00
Opening keynotes
The “Prometheus” basic science and “Hippocrates” clinical science keynote lectures.
Thu & Fri · posters also Sat
Posters and rapid-fire abstracts
Dedicated poster viewing and short oral presentations of selected abstracts.
Thu, Dec 10 · 18:45–19:45
Welcome reception
Joint poster viewing to close the first day.
Fri, Dec 11 · 07:00 (to be confirmed)
Ken Fearon Career Café
Meet the Mentor, with attendance upon application and confirmation.
Fri, Dec 11 · 08:30–09:30 · Hall B
COACH-ED session
Crosstalks on diagnosing and treating cancer cachexia, from oncology and palliative care to nutrition and trials.
Sat, Dec 12 · 08:00–09:00 · Hall A
Young Investigators Award Session
Early-career researchers present their work to the judges.
Sat, Dec 12 · 15:15–16:00 · Hall A
Highlights and awards
Highlights in basic science, nutrition, sarcopenia and cancer cachexia, the Poster Award and the Young Investigator Award.
Heard in the hallways of SCWD
Short interviews recorded at last year’s conference, with researchers from Texas, Toronto and Edinburgh.
SCWD conference interviews. Press play to watch here.
Expert voices
0:53
James CarsonTexas A&M University, College Station, Texas
0:53
Christopher PerryYork University, Toronto
0:38
Richard SkipworthUniversity of Edinburgh
Moving cancer cachexia care forward.
Jeffrey Crawford
Jeffrey CrawfordDuke University School of Medicine
Interview published by COACH-ED · Emerging treatments and clinical trials.
The science brings us together.
Across SCWD conferences: scientific exchange, conversations over coffee and a community moving research forward.
Across SCWD conferences
Scientific exchange, in the room.Conversations beyond the lecture hall.A shared focus on the science.Conversations over coffee.Research becomes a conversation.Celebrating scientific exchange. Photo shared by Henning Langer on LinkedIn.Clinical expertise on stage.Celebrating research.Time to meet and exchange.Sharing new findings.Recognition and community.
Our sponsors
Together for a healthier tomorrow.
Organisations that have supported SCWD conferences, advancing research and patient care.
Previous conference supporters. The 2026 sponsor line-up will be confirmed separately.
Registration fees for in‑person attendance
Late registration fees for in-person attendance.
USD display equivalents. Final booking totals are confirmed in EUR.
Choose your registration category
SCWD 2026 · Washington, DC · December 10–12 · Late registration fees
Medical Professional
1,020EUR
SCWD members: −EUR 255. Sign in at checkout to apply your reduction.
In-person conference registration.
Doctors under 35, scientists, nurses & students
800EUR
SCWD members: −EUR 200. Sign in at checkout to apply your reduction.
Choose this fee if you belong to one of these categories.
Industry representative
2,250EUR
Individual in-person registration for industry representatives.
Selected: Medical Professional
Add Full membership and save EUR 105 overall
Your annual membership costs EUR 150 and reduces this ticket by EUR 255.
Associate: nurses, technicians and doctors under 35. Other scientists and students should check Full eligibility.
Ticket + membership: EUR 915 instead of EUR 1,020 for the ticket alone.
Already an active SCWD member? Sign in to apply your benefit without purchasing a new membership.
Conference ticketEUR 1,020
Full annual membershipEUR 150
Membership reduction−EUR 255
TotalEUR 915
SCWD 2026 in-person registration fees
Category
Registration fee
Medical Professional
Registration feeUSD1,152
SCWD members: −USD288. Sign in at checkout to apply your reduction.
Doctors under 35, scientists, nurses and students
Registration feeUSD904
SCWD members: −USD226. Sign in at checkout to apply your reduction.
Industry representative
Registration feeUSD2,542
Member rates
Sign in at checkout to apply an active, eligible SCWD membership reduction. Membership is a separate annual purchase: SCWD membership.
Letters of invitation for visa purposes are provided by the SCWD office on request: scwd@mededgs.com. The letter is not a commitment to any financial support. If you travel from outside the United States, check entry requirements early.
Choose the category that matches your professional role: Medical Professional; Doctors under 35, scientists, nurses and students; or Industry representative. Each category has a non-member and an SCWD member rate.
Not sure which one fits? Email scwd@mededgs.com before you register.
Are fees in US dollars?
USD and CAD are display equivalents. The native booking form confirms the final amount; the current checkout charges in EUR.
How do SCWD member rates work?
Member rates are available to SCWD members. Membership is a separate purchase with its own conditions, described on the membership page.
If an institution or a third party pays for your registration, send the invoicing address (and VAT number, where applicable) to scwd@mededgs.com before payment. Payment by bank transfer is accepted on request.
What does my registration include?
[À confirmer par l'organisateur. Question masquée en version visiteur.]
Is the conference open to patients or the public?
SCWD 2026 is a scientific conference for healthcare professionals, researchers and industry. It does not provide medical advice or patient care.
Who organises SCWD 2026?
The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD), a scientific society based in Switzerland. Washington, DC is the location of the 2026 conference.
SCWD 2026 is the society’s 19th International Conference.
Stay Informed with the Latest Updates and Exclusive Insights!
Manage Cookie Consent
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Interview published by COACH-ED · Emerging treatments and clinical trials.
Washington, DC
Interview published by COACH-ED · Emerging treatments and clinical trials.
Teresa ZimmersOHSU
Kamyar Kalantar-ZadehUCLA · Harbor-UCLA
Eric RoelandOHSU
Marilia SeelaenderUniversity of São Paulo
Denis GuttridgeMUSC
Jeffrey CrawfordDuke University
Washington, DC
Oregon Health & Science University
0:53
0:53
